Artigos de revistas sobre o tema "LPC Caen"

The 19 F(n,α)16 N cross section is of great interest for the development of the next generation IV reactors that could potentially use molten fluoride salts. Significant differences (up to a factor of 3) have been observed for this nucleus regarding the (n,α) channel. In view of improving our knowledge on this (n,α) reactions, the GrACE group (Groupe Aval du Cycle Electronucl´eaire) of the LPC Caen has developed a new detector named SCALP (Scintillating ionization Chamber for ALPha particle detection in neutron induced reactions). This paper deals with the first experiment carried out with this brand new detector at the new NFS facility (GANIL, Caen, France). After discussing the needs for new measurments of the 19 F(n,α)16 N reaction, the operating procedure of the SCALP detector will be presented, as well as the experiments that have been conducted using it. Furthermore, insights into the data acquired during our experiment, as well as the ongoing data processing and associated multi-channel analysis, will be provided.

In nuclear reactors operating in nominal conditions, delayed neutrons (DN) drive the kinetic behavior of the neutron population. Predicting this behavior requires therefore the knowledge of the DN yield per fission, average lifetime, and kinetic of their emission, which is described by precursors groups abundances. Characterizing the uncertainties of these macroscopic data is essential, especially as they are used to design the safety margins of reactors. Even for major fissile isotopes such as 235U and 239Pu, discrepancies still appear between the main nuclear data library. In 2018, CEA launched the ALDEN project (Average Lifetime of DElayed Neutrons), gathering several laboratories (CEA/DES and DRF, CNRS/LPSC, LP2i and LPC Caen, ENSICAEN, and University of Caen). This collaboration aims at producing new precise DN macroscopic data for reactor applications. Three experimental campaigns were conducted in 2018, 2019 and 2021 on the thermal fission of 233U, 235U and 239Pu at Institut Laue Langevin in Grenoble (France), giving high quality results. In February 2023, a new campaign was performed at the PTB Ion Accelerator Facility in Braunschweig (Germany), focusing on the fast fission of 238U. In particular, the DN yield was measured for eight energies between 1.5 and 19 MeV. This paper presents the experimental setup, that was adapted to the new facility and neutron spectrum. The methodology of analysis is also detailed, and some preliminary delayed neutron decay curves are showed.

In the normal operation of nuclear reactors, the kinetic behavior of the neutron population in the core is driven by the so-called delayed neutrons (DN). The DN yield per fission, their average lifetime and their groups’ abundances are the main physical parameters used to predict the kinetic behavior of the reactor and its reactivity. The overall uncertainty associated to reactivity predictions, which is linked directly to the nuclear reactor safety margins, is thus closely dependent on a few parameters associated with DN. Depending on the nuclear data library, DN kinetic parameters present significant discrepancies, even for major fissile isotopes such as 235U or 239Pu. In this context, CEA has long been working for improving DN nuclear data. In 2018, CEA launched the ALDEN project (Average Lifetime of DElayed Neutrons) in the framework of a collaboration between CEA/DES, CEA/DRF, CNRS/IN2P3 (LPSC, CENBG, LPC), ENSICAEN and Caen University. This program aims at measuring the kinetics of the delayed neutrons to derive the DN yield, their average lifetime and abundances. Two experimental campaigns focusing on the thermal fission of 235U were conducted in 2018 and 2019. They demonstrated the concept feasibility and gave high quality estimations of the DN multiplicity (1.631 ± 0.014 %) and average lifetime (8.82 ± 0.6 s) for 235U. More recently in March 2021, a more ambitious irradiation campaign was conducted on 239Pu and 233U. This paper details the new experimental setup, which was upgraded to meet ILL safety requirements for handling plutonium. The data analysis process is presented, with a focus on the problem of dead time correction. Finally, some preliminary delayed neutron decay curves are showed and discussed.

Abstract One of the aim of the new project Selective Production of Exotic Species (SPES) is to produce and select new, neutron reach, isotopes [1,2,3,4]. The technique adopted to produce these species is the Isotope Selection On Line (ISOL) that postpones the separation of the isotopes after the beam production, using a High-Resolution Mass Spectrometer (HRMS). In order to allow a good separation of isotopes , the transverse emittance and the energy spread of the beam should have very low values, for this reason the Beam Cooler (BC) is located between the ISOL target, i.e. the beam source, and the HRMS. In the SPES project, where heavy isotopes are expected (mass number >100), the spectrometer resolution must be preferably higher than dm/m = 5 × 10-5 and thus the features of the beam at the entrance of the HRMS should be at least εn 95% < 8.3 × 10-3 π mm mrad and σE < 1.5 eV. BC devices are devoted to improve the beam features in terms of emittance and energy spread. A new BC has been designed and realized by the Laboratoire de Physique Corpuscolaire (LPC) at Caen, France, for the SPES facility at Laboratori Nazionali di Legnaro (LNL), near Padova, Italy. BCs cool down the beam thanks to a dissipative process in which the thermal energy passes from the beam ions to another medium whose constituent is typically much lighter, Helium gas in our case. This process takes place inside a confinement system that on the one hand to limit the spread of the cooling medium, and on the other to allow the beam to continue along the required trajectory, in the presented device it is a row of radio frequency quadrupoles in an almost closed chamber. Some specifications of the BC described in this document: the RFQ is 723 mm long, its internal radius is 5 mm; the RFQ is included in the gas chamber which is 730 mm×280 mm×220 mm. Before it there is the injection part composed by, following the beam trajectory, a grounded pipe (388 mm long) and three focusing electrodes. On the opposite side there is the extraction part with two focusing electrodes. This document presents the main features of the new BC together with the results of a preliminary study where the beam dynamic has been simulated. The analysis embeds also the investigation of the gas distribution inside and outside the BC. The beam dynamic simulations are based on the Simion code [5] while the estimation of the gas distribution is computed with MolFlow+ [6]. Simulations show that accurately setting the BC leads to a large improvement of the emittance while the energy spread still needs to be improved. Limiting the gas pressure in the acceleration zone seems to allow the required final boost.

Structura sectorului forestier ca parte a economiei naționale în care are loc producția și comercializarea produselor lemnoase ale pădurii oferă informații importante pentru formularea unor strategii de gestionare durabilă a resursei forestiere, dar și de formulare a unor politici publice de stimulare a folosirii resursei lemnoase în produse de lemn de lungă durată, de asigurarea sustenabilă a resursei pentru producerea de energie verde și pentru utilizarea multi-ciclică a lemnului, așa cum este prevăzut și în strategia forestieră națională. Prezentul studiu își propune să contribuie la clarificarea unor aspecte privind atributele structurale ale cererii de masă lemnoasă pentru utilizare industrială, având ca obiective: 1) analiza caracteristicilor structurale ale sectorului forestier și a importanței sale în economia românească; 2) evaluarea interdependențelor existente între diferitele segmente ale sectorului; 3) analiza mediului concurențial. Caracterizarea structurală a sectorului forestier se bazează pe informațiile standardizate culese la nivelul țării de Institutul Național de Statistică. Operatorul de bază îl constituie codul CAEN (Clasificarea Activităților din Economia Națională) pe baza căruia, fiecare firmă înregistrată în România operează activități dintr-un anumit domeniu economic. CAEN (Rev.1, Rev.2)[1] reprezintă un acronim utilizat în clasificarea statistică națională a activităților economice din România CAEN Rev. 2 reprezintă varianta revizuită a CAEN Rev 1, fiind realizată în concordanță cu versiunea europeană (NACE Rev. 2, elaborată de EUROSTAT), publicată în Jurnalul Oficial al Uniunii Europene. Versiunea revizuită a intrat în vigoare la 1 ianuarie 2008. Toate documentele privind înregistrarea unei firme la Registrul Comerțului trebuie să fie întocmite potrivit CAEN Rev. 2. Pentru a răspunde primului obiectiv al studiului, baza de date statistice referitoare la agenții economici din sectorul forestier a fost interpretată în funcție de alte informații referitoare la forța de muncă totală ocupată în industria prelucrătoare, contribuția sectorului la PIB, contribuția sectorului în exportul României și alți indicatori socio-demografici și de resursă forestieră existenți la nivel de județe, macroregiuni și regiuni de dezvoltare Pentru a răspunde celui de-al doilea obiectiv al studiului s-a cercetat econometric conexiunea dintre Exploatarea forestieră și industriile de prelucrare a lemnului, care au fost analizate în dinamică, în perioada 2015 - 2019. Modelul pornește de la evaluarea eficienței exploatării lemnului în comparație cu eficiența înregistrată în industriile prelucrătoare de tăierea și rindeluirea lemnului, fabricarea de furnire și panouri de lemn sau fabricarea de mobilă pentru birouri și magazine, fabricarea de mobilă pentru bucătării. Pentru cel de-al treilea obiectiv- analiza mediului concurențial al sectorului forestier din Romania am utilizat mai mulți indicatori sectoriali (Consiliul Concurenței, 2012:6), precum: numărul de firme, cifra medie de afaceri/salariat în sector, indicele Herfindahl-Hirshman (IHH), rata de concentrare, gradul de concentrare al pieței și indicele Pareto (numărul celor mai mari firme de exploatare care reprezintă 20% din numărul total de firme pe segmentul exploatare forestieră în județul respectiv, și procentul cifrei de afaceri totalizat de firmele de mai sus

To promote crystallography through the "Midi-Pyrénées" Region, our association, « Les Cristallographes en Midi-Pyrénées » has scheduled different events from October 2013 until the end of 2014. These events will cover scientific demonstrations and/or lectures open to the general public. 1) Events - The Novela (7-12 October 2013), organized by the Toulouse-Metropole, is an event whose major goal is to share knowledge, in all its diversity, in a festive and popular spirit. It aimed at pupils and students as well as the general public. This will be performed once again in October 2014. - The "Kiosque-Actu" at the Toulouse Museum provides an opportunity to inquire and to exchange with researchers on a scientific topical subject. On the 2nd of February 2014, researchers coming from several laboratories in Toulouse (CEMES, CIRIMAT, GET, IPBS, and LCC; from the CNRS and the Paul Sabatier University) and involved in all domains of X-ray diffraction (Biology, Mineralogy, Chemistry, Materials, etc.) came to meet the general public and to demonstrate the importance of crystallography. Exhibition "Voyage dans le cristal / Journey within a crystal" at (i) the Philadelphe Thomas Museum in Gaillac (14 February-4 May 2014) and (ii) at the library of the Paul Sabatier University (from the 1st of September until the end of the year). Panels from this exhibition have been/will be also displayed during all events mentioned above. 2) Conferences - Maryvonne Hervieu (ENSICAEN, Caen, France), 17 February 2014, "Des cristaux et des hommes / Of crystals and men". - Jean-Claude Daran (LCC, Toulouse, France), 20 February 2014, "Les cristaux de Louis Pasteur / Louis Pasteur's crystals". - Lionel Mourey (IPBS, Toulouse, France), 27 February 2014, "Des cristaux au secours de la médecine / Crystals to help medicine". - Anne-Magali Seydoux (GET, Toulouse, France), 10 April 2014, "Effets de la radioactivité sur les structures des minéraux / Effects of radioactivity on the structure of minerals".

Purpose China’s rapid pace of urbanization has resulted in millions of rural residents migrating from rural areas to urban areas for better job opportunities. Due to economic pressures and the nature of China’s demographic policies, many of these migrants have been forced to leave their children with relatives – typically paternal grandparents – at home in the countryside. Thus, while income for most migrant families has risen, a major unintended consequence of this labor movement has been the emergence of a potentially vulnerable sub-population of left-behind children (LBCs). The purpose of this paper is to examine the impacts of parental migration on both the academic performance and mental health of LBCs. Design/methodology/approach Longitudinal data were drawn from three waves of a panel survey that followed the same students and their families – including their migration behavior (i.e. whether both parents, one parent, no parent migrated) – between 2015 and 2016. The survey covers more than 33,000 students in one province of central China. The authors apply a student fixed-effects model that controls for both observable and unobservable confounding variables to explicate the causal effects of parental migration on the academic and mental health outcomes for LBC. The authors also employ these methods to test whether these effects differ by the type of migration or by gender of the child. Findings The authors found no overall impact of parental migration on either academic performance or mental health of LBCs, regardless of the type of migration behavior. The authors did find, however, that when the authors examined heterogeneous effects by gender (which was possible due to the large sample size), parental migration resulted in significantly higher anxiety levels for left-behind girls. The results suggest that parental migration affects left-behind boys and girls differently and that policymakers should take a more tailored approach to addressing the problems faced by LBCs. Originality/value The main contributions of this paper come from the large and representative sample, as well as the causal effects analysis of being left-behind on both academic performance and mental health. First, the paper uses comprehensive panel data from a representative and populous province in China, and the sample size is the largest one among LBC-related papers to the authors’ knowledge. Second, the paper separately examines the causal effects on the student outcomes of different migration strategies. Third, the paper analyzes the heterogeneous effects of different migration strategies on LBC gender. The authors believe that the paper makes a key contribution to the literature.

Abstract Introduction: The use of lenalidomide (len) in the treatment of newly diagnosed multiple myeloma (NDMM) as induction and/or maintenance therapy is increasing. The majority of patients (pts) progress and require further treatment, highlighting a need for effective regimens for these len-exposed and len-refractory RRMM pts. Daratumumab (DARA) is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action. In three phase 3 studies, the addition of DARA to standard of care (SOC) regimens has doubled complete response (CR) rates, tripled minimal residual disease (MRD)-negative rates, and reduced the risk of progression or death by ≥50% vs SOC alone in RRMM and NDMM pts (Palumbo A, et al. N Engl J Med 2016. 375[8]:754-766; Dimopoulos MA, et al. N Engl J Med 2016. 375[14]:1319-1331; Mateos MV, et al. N Engl J Med 2018. 378[6]:518-528). To evaluate the efficacy of DARA plus SOC regimens in RRMM pts previously exposed or refractory to len, we evaluated data from relevant subpopulations of patients in the phase 3 CASTOR and POLLUX studies and the phase 1 MMY1001 study. Methods: CASTOR and POLLUX are both open-label, randomized, phase 3 studies of DARA plus bortezomib/dexamethasone (D-Vd) or lenalidomide/dexamethasone (D-Rd), respectively, vs SOC alone in RRMM pts with ≥1 prior line of therapy. Len-refractory pts were ineligible for POLLUX. Within MMY1001, a multi-arm phase 1b study, RRMM pts treated with DARA plus carfilzomib/dexamethasone (D-Kd) or pomalidomide/dexamethasone (D-Pd) were included in this analysis. In the phase 3 studies, progression-free survival (PFS) was assessed in the intent-to-treat (ITT) population and were compared using a stratified log-rank test. Responses were assessed in an evaluable population defined as pts with measurable disease at baseline and ≥1 post-baseline disease assessment. Minimal residual disease (MRD) was evaluated in the ITT population using clonoSEQ® V2.0 (Adaptive Biotechnologies, Seattle, WA). Results: Median (range) number of prior lines received was 2 (1-10) in CASTOR, 1 (1-11) in POLLUX, 2 (1-4) in the MMY1001 D-Kd cohort, and 4 (1-13) in the MMY1001 D-Pd cohort. A total of 493 pts (323 pts treated with DARA) received prior len across the 3 DARA studies. Among len-exposed pts in CASTOR (D-Vd, n = 89; Vd, n = 120), median PFS was 9.5 vs 6.1 months (hazard ratio [HR] 0.40; 95% confidence interval [CI], 0.28-0.58; P <0.0001) after median follow up of 31.3 months. A similar PFS HR was reported for len-exposed pts in POLLUX (D-Rd, n = 50; Rd, n = 50) after median follow up of 39.5 months, in which D-Rd treated pts demonstrated significantly longer PFS vs Rd treated pts (median: 38.9 mo vs 18.6 mo; HR 0.39; 95% CI, 0.22-0.70; P = 0.0010). In both the CASTOR and POLLUX studies, rates of deeper responses and MRD-negative rates at 10-5 sensitivity threshold were all significantly higher (P <0.05 for all comparisons) for DARA-containing regimens vs SOC alone (Table). A total of 284 pts (203 pts treated with DARA) were len-refractory across CASTOR and MMY1001. Among 60 D-Vd and 81 Vd len-refractory pts in CASTOR, median PFS was 7.8 vs 4.9 months (HR 0.44; 95% CI, 0.28-0.68; P = 0.0002). Significantly higher response and MRD-negative rates at 10-5 were observed for D-Vd vs Vd in len-refractory pts (Table). In MMY1001, nearly all pts treated with D-Kd (n = 81/85) or D-Pd (n = 103/103) were exposed to len, and the majority of pts treated with D-Kd (n = 51/85) or D-Pd (n = 92/103) were len-refractory. Among all pts, median PFS was not reached for D-Kd after median follow-up of 12 months (12-mo PFS rate: 62%), and median PFS was 9.9 months for D-Pd after median follow-up of 28.1 months. Among the 51 len-refractory pts treated with D-Kd, median PFS was 14.1 months. In all-treated pts, ORR was 66% for D-Pd and 84% for D-Kd (79% for the len-refractory subgroup). Updated data from all 3 studies will be presented at the meeting. Conclusion: In len-exposed or -refractory patients, DARA enabled deep responses and prolonged PFS irrespective of the SOC combination partner and number of prior lines of treatment. DARA-based regimens were more effective in less heavily pretreated len-exposed or len-refractory pts, suggesting earlier use (eg, after first relapse) would provide a greater benefit. Disclosures Usmani: Abbvie, Amgen, Celgene, Genmab, Merck, MundiPharma, Janssen, Seattle Genetics: Consultancy; Amgen, BMS, Celgene, Janssen, Merck, Pharmacyclics,Sanofi, Seattle Genetics, Takeda: Research Funding. Mateos:Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Lentzsch:Caelum Biosciences: Consultancy, Other: Dr. Lentzsch recused herself as an investigator from the Phase 1a/b trial testing CAEL-101 in 11/2017., Patents & Royalties: Shareholder for Caelum Biosiences; BMS: Consultancy; Janssen: Consultancy; Bayer: Consultancy. Quach:Celgene: Consultancy, Research Funding; Janssen Cilag: Consultancy; Sanofi Genzyme: Research Funding; Amgen: Consultancy, Research Funding. Capra:Janssen: Research Funding, Speakers Bureau; Roche: Speakers Bureau; Amgen: Speakers Bureau; AbbVie: Research Funding; Sanofi: Research Funding; Bristol Myers Squibb: Research Funding; Novartis: Research Funding. Sonneveld:Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Karyopharm: Honoraria, Research Funding; BMS: Honoraria, Research Funding. Qi:Janssen Research & Development, LLC: Employment. Amin:Janssen Research & Development, LLC: Employment. Wang:Janssen Research & Development, LLC: Employment. Qin:Janssen Research & Development, LLC: Employment. Okonkwo:Janssen Research & Development, LLC: Employment. Ukropec:Janssen Scientific Affairs, LLC: Employment. Trivedi:Janssen Research & Development, LLC: Employment. Suzuki:Takeda: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Ono: Consultancy, Honoraria; Sanofi Aventis: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; SRL.Inc: Employment. Dimopoulos:Bristol-Myers Squibb: Honoraria; Janssen: Honoraria; Amgen: Honoraria; Takeda: Honoraria; Celgene: Honoraria. Cavo:GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Nooka:Adaptive technologies: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Spectrum Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees. Chari:Array Biopharma: Research Funding; The Binding Site: Consultancy; Adaptive Biotechnology: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy; Pharmacyclics: Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Facon:Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees.

Se describe lo que le sucedería a un observador al caer hacia el horizonte de sucesos de un agujero negro de Schwarzschild, así como la existencia de una órbita circular estable alrededor de dicho agujero. También se analiza la posible producción de agujeros negros cuánticos en aceleradores de partículas como el LHC.

Introduction: Speech Sound Disorder (SSD) is a speech and language disorder associated with difficulties in motor production, perception, and phonological representation of sounds and speech segments. Since auditory perception has a fundamental role in forming and organizing sound representation for its recognition, studies that evaluate the cortical processing of sounds are required. Thus, the present study aimed to verify the relation between SSD severity measured by the Percentage of Correct Consonants (PCC) with the cortical auditory evoked potentials (CAEP) using speech stimulus. Method: Twenty-nine children with normal hearing participated in this research and were grouped into three groups by SSD level measured by the PCC index. In addition, the groups were subdivided according to the children’s age group: between 60 to 71 months, 72 to 83 months, and 83 to 94 months. The CAEP with speech stimulus was carried out in all children. Results: Older children had longer P1 and N1 latencies. In P2 latency, there was an interference of age only in the severe group. The N2 latency was affected by age, where older children had longer latency. Conclusion: The amplitude of CAEP has not suffered any interference with the age, or severity of SSD. For the latency, older children generally presented longer averages than younger ones.